Todd Davis: Swissmedic has approved FILSPARI for the treatment of adults with primary IgA nephropathy
Todd Davis, Chief Executive Officer & Director at Ligand Pharmaceuticals, shared on LinkedIn:
“We have had several exciting events across the Ligand Pharmaceuticals portfolio recently.
Last week, Travere Therapeutics and CSL announced that Swissmedic has approved FILSPARI for the treatment of adults with primary IgA nephropathy. This product is a growing part of our commercial royalty portfolio, and we are excited to see more widespread adoption of this groundbreaking therapy for kidney disease.
On Wednesday the CDC’s Advisory Committee on Immunization Practices recommended Merck’s CAPVAXIVE for adults 50 and older. This decision lowers the current age-based recommendations for adult pneumococcal vaccination from 65 to 50 which is a significant positive development.
You can read more about these news developments at Ligand Pharmaceuticals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023